The OPAL Study: A Phase II Study to Evaluate the Efficacy, Safety and Tolerability of Tosedostat (CHR-2797) in Elderly Subjects with Treatment Refractory or Relapsed Acute Myeloid Leukemia (CHR-2797-038).

Trial Profile

The OPAL Study: A Phase II Study to Evaluate the Efficacy, Safety and Tolerability of Tosedostat (CHR-2797) in Elderly Subjects with Treatment Refractory or Relapsed Acute Myeloid Leukemia (CHR-2797-038).

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Jan 2016

At a glance

  • Drugs Tosedostat (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Acronyms OPAL; TOPAZ
  • Sponsors Chroma Therapeutics
  • Most Recent Events

    • 04 Mar 2013 Results from the OPAL trial have been published in Lancet Oncology according to a Cell Therapeutics media release. Results were also summarised in the media release.
    • 14 Feb 2012 Actual patient number changed from 73 to 76 as reported by ClinicalTrials.gov (Parent trial: NCT00780598).
    • 14 Feb 2012 Actual patient number changed from 73 to 76 as reported by ClinicalTrials.gov (Parent trial: NCT00780598).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top